Sensorion

140 articles about Sensorion

• Sensorion Receives European Medicines Agency Agreement on the Pediatric Investigation Plan (PIP) for Arazasetron (SENS-401) in Two Indications

  6/28/2019

  Sensorion announces that the European Medicines Agency has accepted its Pediatric Investigation Plan for both development in the treatment of severe hearing loss and for prevention of ototoxicity caused by cisplatin in the pediatric population.

• Sensorion Announces That the “AUDINNOVE” Project of Which Sensorion Is a Partner Is a Laureate of the Fourth Solicitation Request for Funding From RHU as Part of the French “Avenir Investment Program”

  6/26/2019

  The "AUDINNOVE" project led by AP-HP in partnership with Institut Pasteur, “la Fondation pour l’Audition” and Sensorion will receive a € 9.7m grant funding

• 

  BioSpace Global Roundup, June 13

  6/13/2019

  Companies from across the globe share business and pipeline updates.

• Sensorion Announces a €20m Convertible Bond Issue Subscribed by Two Renowned Investors Invus and Sofinnova Partners

  6/12/2019

  Sensorion announces a convertible bond issue with a nominal value of 20 million euros subscribed by two new investors, Invus Public Equities LP as the anchor investor and Sofinnova Crossover I SLP as co-anchor investor.

• Sensorion Announces Poster Presentation at the “Société Internationale d’Otoneurologie” Symposium

  6/3/2019

  Presentation of SENS-111 phase 2 study protocol in Acute Unilateral Vestibulopathy (AUV)

• Sensorion: Reporting of the General Assembly

  5/29/2019

  Sensorion a pioneering clinical-stage biopharmaceutical company which specialises in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo held its combined general meeting on May 28, 2019.

• Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing Loss

  5/27/2019

  This agreement defines an exclusive option to obtain licences for joint programs including Otoferlin & Usher Type 1 and preference rights on the research pipeline in the field of genetic disorders of the inner ear in order to set up future collaborations

• Sensorion announces oral presentation at the European Histamine Research Society

  5/17/2019

  Sensorion a pioneering clinical-stage biopharmaceutical company which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, will present a keynote plenary lecture at the European Histamine Research Society in Kraków, Poland from May 15-18th, 2019.

• Sensorion Announces the Positive Data Safety Monitoring Board (DSMB) Review and Continuation of the Phase 2 Clinical Trial for SENS-111 in Acute Unilateral Vestibulopathy (AUV)

  5/15/2019

  Sensorion announced that the independent Data Safety Monitoring Board has undertaken a review of the safety data for the 76 first patients having completed the phase 2 clinical trial for SENS-111 in the treatment of acute unilateral vestibulopathy.

• Sensorion Reports Its 2018 Annual Results; 75% of Patients Enrolled in the Sens-111 Clinical Trial

  3/27/2019

  SENS-111 phase 2 AUV trial: major progress with 75% of patients enrolled in the clinical trial assessing the efficacy of SENS-111 on vertigo intensity

• Sensorion strengthens its financial structure by issuing a €4.7 million nominal bond issue subscribed by new European investors and management

  3/11/2019

  Sensorion announced a €4.7 million nominal bond issue, consisting of one (i) convertible bond issue1 for a nominal amount of €3,4 million subscribed by several new European investors as well as a bond issue2 for a nominal amount of €1.3 million subscribed by these same European investors for an amount of €1 million and the balance by the Company's management, Mr. Patrick Langlois, Chairman of the Board of Directors and Ms. Nawal Ouzren, Chief Executive Officer.

• 

  Sensorion and Cochlear Announce Collaboration to Study Combination Therapies for Cochlear Implant...

  12/19/2017

  The collaboration will evaluate therapeutic approaches using SENS-401 in combination with cochlear implants, with preclinical studies initiating in 2018, and potential clinical trials to begin as soon as 2019.

• Sensorion Reports 2017 First-Half Results

  10/19/2017

  Sensorion announces its results for the first half of the year ending June 30, 2017, as well as its recent developments.

• Sensorion Announces Positive Results From SENS-218 Phase I Clinical Trial Undertaken In The UK

  9/7/2016

• Sensorion To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

  9/1/2016

• Sensorion Obtains FDA Approval To Initiate A Clinical Study Of SENS-111 In Acute Severe Vertigo

  9/1/2016

• Sensorion Strengthens Its Financial Structure With The Exercise Of The Second Tranche Of Its Financing Agreement

  8/18/2016

• Sensorion To Present Data From Phase Ib Clinical Trial Of SENS-111 At AAO-HNSF Annual Meeting

  5/12/2016

• Sensorion Receives Approval From The UK Drug Agency To Initiate Clinical Trial Of SENS-218

  1/6/2016

• Sensorion, The Specialist In Inner Ear Diseases, Completes A New Funding Round To Begin The Human Clinical Trial Phase

  1/20/2015